You are here

hepatitis C

EU withdraws marketing authorisation for Abbvie's hepatitis C drug

Reuters

Wed, 10/2/24 - 11:16 am

First hepatitis C self-test prequalified by WHO

Clinical Trials Arena

Mon, 07/15/24 - 09:55 am

OraQuick HCV self-test

Boosting hepatitis C treatment would save money, CBO says

Axios

Tue, 06/18/24 - 11:37 am

Hepatitis B drug developers chart slow progress forward, just like hep C before it

Fierce Biotech

Tue, 11/14/23 - 09:35 am

drug development

Assembly Biosciences

Aligos Therapeutics

Biden budget wants to more than double number of negotiated drugs under Medicare, and eliminate hepatitis C

Endpoints

Thu, 03/9/23 - 10:13 pm

Oncology, HIV sales lift Gilead’s revenues by 2%

Medical Marketing and Media

Thu, 02/2/23 - 11:09 pm

Gilead Sciences

With a promising new plan to pay for pricey cures, two states set out to eliminate hepatitis C. But cost hasn’t been the biggest problem

Stat

Wed, 09/14/22 - 09:26 am

Washington state

FDA shakes up hepatitis C testing market by opening up 510(k) pathway

Medtech Dive

Mon, 11/22/21 - 10:30 am

FDA Approves Gilead’s Epclusa for Children with Hepatitis C

BioSpace

Fri, 03/20/20 - 10:43 am

Gilead Sciences

European regulators expand use of AbbVie's two-month hep C regimen

Endpoints

Fri, 03/6/20 - 10:39 am

Where Will Gilead Sciences Be in 10 Years?

Motley Fool

Sat, 02/22/20 - 11:23 pm

Gilead Sciences

Enanta Pharmaceuticals' Q4 Results Pulled Down by AbbVie's Sinking HCV Sales

Motley Fool

Fri, 11/22/19 - 10:04 am

Enanta Pharmaceuticals

Merck loses bid to revive $2.54 billion patent verdict against Gilead

Yahoo/Reuters

Wed, 10/30/19 - 10:18 am

Gilead Sciences

State-Pharma Deals for Hepatitis C Drugs Come Under Scrutiny

BioSpace

Fri, 10/25/19 - 10:48 pm

Washington state

Gilead Sciences

Asegua Therapeutics

FDA clears shorter treatment regimen for AbbVie's hep C treatment, Mavyret. Will patients benefit?

Endpoints

Mon, 09/30/19 - 10:42 am

FDA issues safety warning for newer hepatitis C drugs following patient deaths

Biopharma Dive

Wed, 08/28/19 - 11:02 pm

Gilead Sciences

5 Things You Need to Know From AbbVie's Q2 Earnings Results

Motley Fool

Sat, 07/27/19 - 02:03 pm

JAMA: Withdraw This Flawed and Inaccurate Article About the 340B Program and Drug Prices

Drug Channels

Tue, 07/16/19 - 11:10 pm

CMS approves Louisiana's 'Netflix model' with Gilead for hepatitis C drugs

Biopharma Dive

Wed, 06/26/19 - 11:49 pm

Gilead Sciences

June 14 P&P Quick Takes: Washington state approved for subscription HCV model; plus Merck and IBM, BGI, and more

BioCentury

Sat, 06/15/19 - 05:54 pm

Pages